{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"13.9","upperLimit":"28.3","value":"20.5"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"132"}],"units":"Participants"}],"description":"ORR was defined as the percentage of participants in the analysis population who experienced a CR (disappearance of all target lesions) or a PR (at least a 30% decrease in the sum of diameters of target lesions) and was assessed by Investigator evaluation. The percentage of participants who experienced a CR or PR in Cohort B2 based on investigator assessment was presented for the first course of pembrolizumab treatment per protocol. ORR per RECIST 1.1 based on investigator assessment was presented for the other cohorts in a separate outcome measure.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received pembrolizumab, 200 mg, IV once every 3 weeks, and continued to receive study drug until disease progression, death, withdrawal of consent, Investigator decision, or end of study (up to 2 years). Participants who stopped study treatment without progression (e.g. completed 2 years) may have been eligible for up to 1 year of retreatment upon subsequently experiencing disease progression.","id":"OG000","title":"Cohort B2: Head & Neck Cancer Expansion"}],"paramType":"NUMBER","populationDescription":"The population consisted of all Cohort B2 participants who received ≥1 dose of study treatment.","reportingStatus":"POSTED","timeFrame":"Every 8 weeks until disease progression (Up to ~ 35 months) - through FA cutoff date 26 Apr 2016","title":"Overall RECIST 1.1 Response Rate Based on Investigator Assessment for Cohort B2","type":"SECONDARY","unitOfMeasure":"Percentage of Participants"}